WANTAI BIOLOGICAL(SH:603392) 36氪·2025-10-04 04:08Group 1 - The article highlights the alarming statistics of cervical cancer, with 156,000 new cases and nearly 60,000 deaths in China in 2022, accounting for about 20% of global cases [3] - HPV vaccine is the only cancer that can be prevented through vaccination, and the article discusses the high demand and supply issues surrounding the HPV vaccine in China [4][8] - The introduction of domestic HPV vaccines has significantly reduced prices, with the first domestic bivalent HPV vaccine priced at 329 yuan, compared to over 6,000 yuan for imported vaccines [23][29] Group 2 - The article details the successful initiative in Ordos, Inner Mongolia, where local government provided free HPV vaccinations to girls aged 13-18, resulting in a vaccination rate exceeding 85% by the end of 2020 [14][18] - The entry of domestic manufacturers like Wantai Biologics has disrupted the market, leading to a significant decrease in vaccine prices and increasing accessibility [20][24] - The inclusion of the HPV vaccine in China's national immunization program marks a significant step towards improving public health and reducing health inequalities [30][34]